

PRESS RELEASE

12 August 2025 08:00:00 CEST

Saniona to present at several conferences in the second half of 2025

Saniona (OMX: SANION), a clinical-stage biopharmaceutical company, will be presenting at several investor and partnering conferences in the second half of 2025.

Below an overview of places where you can currently meet Saniona and hear more about our programs and strategy. Please also visit our website www.saniona.com for an updated list of investor and partnering conferences Saniona will attend.

Saniona conference participation:

Pareto Securities - 16th annual health conference, September 16 – Stockholm

Økonomisk Ugebrev – investor conference, September 24 – Copenhagen

Redeye – Neurology event, October 15 – Stockholm

BIO-Europe, November 3 – 5 - Vienna

Biostock – Life science summit, November 12 – 13 – Lund

Dansk aktionærforening – InvestorDagen, November 17 – Copenhagen

Redeye – Life science day, December 3 – Stockholm

For more information, please contact

Johnny Stilou, CFO, +45 21227227; johnny.stilou@saniona.com

About Saniona

Saniona (OMX: SANION) is a clinical-stage biopharmaceutical company focused on neurological and psychiatric diseases. Its internal pipeline includes SAN2219 and SAN2355 for epilepsy and SAN2465 for major depressive disorder. Saniona has two strategic collaborations: one with Acadia Pharmaceuticals, which has licensed worldwide rights to ACP-711 and is preparing it for Phase 2 in essential tremor, and one with Productos Medix, which holds the rights to tesofensine for obesity in Mexico and Argentina and has submitted a market authorization application in Mexico. Saniona also has two clinical programs available for partnership: TesometTM, ready for Phase 2b in rare eating disorders, and SAN903, ready for Phase 1 in inflammatory bowel disease. Saniona's partners also include Boehringer Ingelheim, AstronauTx, and Cephagenix. Based in Copenhagen, Saniona is listed on Nasdaq Stockholm Main Market.

For more information, visit www.saniona.com.

Attachments

Saniona to present at several conferences in the second half of 2025